FLT3 and acute myeloid leukemia: More recently, while targeted agents against specific mutations (e.g., FLT3-ITD or IDH1/2 in AML, CAR-T therapy in ALL) have opened new therapeutic options for some patients, the majority of patients are still treated according to standard chemotherapeutic protocols.